This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
Avatar

ASCO® 2024 Insights: "NEO-TIM Trial - Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-Risk Resectable Melanoma"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Paolo A. Ascierto
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Paolo A. Ascierto
32 views
June 12, 2024

Chapters

NEO-TIM Trial & Drug Combination Overview

00:00

Study Design, Patient Enrollment & Baseline Characteristics

01:40

Clinical Trial Results & Safety Evaluation

04:04

0 Comments
Login to view comments. Click here to Login

2024 ASCO® Annual Meeting Insights Hub: Skin Videos

05:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Biomarker Analysis & Updated Clinical…

Feat. L. Burton
35:23
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

Feat. S. Patel
24:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and A…

Feat. Z. Eroglu
View All

Related Content

AUTOPLAY
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
24:14
Masterclasses in Dermatology

Advances in the Treatment of Melanoma

Feat. D. Fisher
12:46
Stanford Medicine

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Feat. A. Betof Warner
35:23
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

Feat. S. Patel
11:05
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, …

Feat. D. Johnson
25:29
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Insights in Melanoma"

Feat. O. Hamid
22:58
Tarek Haykal

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

09:54
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Ou…

Feat. H. Tawbi
18:28
Vanderbilt University Medical Center (VUMC)

NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…

Feat. D. Johnson
03:55
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib …

Feat. A. Hauschild
09:26
Oncology Data Advisor

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Feat. M. Hadfield
24:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and A…

Feat. Z. Eroglu
14:42
Jeff Yorio

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

22:27
2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde
08:41
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in …

Feat. C. Blank
55:10
University of Colorado Cancer Center

History of Cancer and Its Treatment: What Will It Take to Cure?

Feat. C. Lieu
11:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Curing Stage IV Melanoma - Where Have We B…

Feat. P. Corrie
17:07
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis

Melanoma Brain Metastases: Successes, Failures, and Future Opportuni…

Feat. M. Postow
13:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Expanding the Benefit - Dabrafenib/Tramet…

Feat. V. Subbiah
28:32
West Virginia State Rheumatology Society

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

Feat. J. Bustamante